Troy Wichterman
Chief Financial Officer
Replay available
BioLife Solutions, Inc. (NASDAQ: BLFS) Q1 2025 earnings conference call, held 2025-05-08. Replay captured from the company's public earnings webcast.

Chief Financial Officer
Chief Executive Officer and Chairman
Analyst, Jefferies
Analyst, KeyBank Capital Markets
Analyst, TD Cowen
Analyst, Lake Street Capital Markets
Analyst, Craig Hallam Capital Group
Analyst, Northland Capital Markets
Analyst, HC Wainwright
Good afternoon, ladies and gentlemen, and thank you for standing by. Welcome to the BioLife Solutions First Quarter 2025 Shareholder and Analyst Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. I will now turn the call over to Troy Wichterman, Chief Financial Officer of BioLife Solutions. Please go ahead. Thank you, operator. Good afternoon, everyone, and thank you for joining the BioLife Solutions 2025 First Quarter Earnings Conference Call. On the call with me today is Roderick DeGrief, CEO and Chairman of the Board. We will cover business highlights and financial performance for the quarter and affirm our full-year 2025 financial guidance. Earlier today, we issued a press release announcing our financial results and operational highlights for the first quarter of 2025, which is available at biolifesolutions.com. As a reminder, during this call, we will make forward-looking statements. These statements are subject to risks and uncertainties that can be found in our SEC filings. These statements speak only as of the date given, and we undertake no obligation to update them. We will also speak to non-GAAP or adjusted results. Reconciliations of gap to non-gap or adjusted financial metrics are included in the press release we issued this afternoon. Now, I'd like to turn the call over to Rod DeGrief, Chairman and CEO of BioLife. Thanks, Troy. Good afternoon and thank you for joining us for BioLife's first quarter 2025 conference call. The first quarter marked a strong start to 2025, meeting our expectations as we continue to execute our strategic priorities and build on the momentum of 2024. We delivered solid top line performance with our cell processing revenue in...